Related Experiment Video
Updated: Jan 17, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell
Franck Morschhauser1, Gilles Salles2, Laurie H Sehn3
1University of Lille, Lille, France.
Summary
Polatuzumab vedotin plus R-CHOP (Pola-R-CHP) demonstrated sustained progression-free survival benefits in previously untreated diffuse large B-cell lymphoma (DLBCL) patients over five years. This confirms Pola-R-CHP as a new standard of care for frontline DLBCL treatment.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
- Current frontline treatments like R-CHOP have limitations in achieving long-term remission.
- Novel therapeutic strategies are needed to improve outcomes for DLBCL patients.
Purpose of the Study:
- To evaluate the long-term efficacy and safety of polatuzumab vedotin plus R-CHOP (Pola-R-CHP) versus R-CHOP in previously untreated DLBCL.
- To assess the 5-year progression-free survival (PFS) and overall survival (OS) in the POLARIX study.
- To analyze outcomes in specific patient subgroups and assess long-term tolerability.
Main Methods:
- The POLARIX study (NCT03274492) was a randomized clinical trial comparing Pola-R-CHP to R-CHOP.
- The study included patients with previously untreated intermediate- or high-risk DLBCL.
- Data from a 5-year follow-up were analyzed for PFS, OS, and safety.
Main Results:
- Pola-R-CHP showed a sustained significant PFS benefit over R-CHOP at 5-year follow-up (HR 0.77).
- Five-year PFS rates were 64.9% for Pola-R-CHP and 59.1% for R-CHOP.
- Exploratory analyses indicated favorable survival in high-risk subgroups, with similar long-term tolerability between arms.
Conclusions:
- Pola-R-CHP demonstrates a sustained PFS benefit in frontline DLBCL treatment.
- The findings support Pola-R-CHP as a new standard of care for patients with previously untreated DLBCL.
- Long-term data reinforce the efficacy and acceptable tolerability of Pola-R-CHP.
